Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
524 stopped studies mapped to Lymphoid Leukemia and descendants · 86% state a reason
Over the 524 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02273856 | Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic…(NADIR) | — | terminated | Oct 24, 2014 | Astellas Pharma International B.V. | The study was terminated due to insufficient subject enrollment and very slow enrollment. | Enrollment / accrual |
| NCT00185523 | Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous… | — | terminated | Sep 16, 2005 | Stanford University | not stated | Not stated |
| NCT00751296 | Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia…(Rev-CLL) | Phase 2 | terminated | Sep 11, 2008 | University Health Network, Toronto | Seven years of follow-up \& final analysis done in Dec 2012. | Other (stated, no rule matched) |
| NCT00313053 | Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory… | Phase 1 | terminated | Apr 11, 2006 | Clare Twist | not stated | Not stated |
| NCT00543114 | Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL | Phase 1 | terminated | Oct 12, 2007 | Dana-Farber Cancer Institute | lack of efficacy and tolerability | Efficacy / futility |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | Phase 1 / Phase 2 | terminated | Dec 21, 2007 | Baylor College of Medicine | slow accrual | Enrollment / accrual |
| NCT02556346 | Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose… | Phase 1 | withdrawn | Sep 22, 2015 | Molecular Templates, Inc. | The patient population (CLL \& SLL) was included in another ongoing study involving NHL patients. | Other (stated, no rule matched) |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | Phase 1 | terminated | Apr 23, 2008 | Erimos Pharmaceuticals | Funding constraints | Funding |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced… | Phase 2 / Phase 3 | withdrawn | Jul 7, 2006 | Bristol-Myers Squibb | not stated | Not stated |
| NCT01604031 | Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells +…(TAIL) | Phase 1 | terminated | May 23, 2012 | Baylor College of Medicine | not stated | Not stated |
| NCT01510756 | Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | Jan 16, 2012 | Thomas Kipps | slow enrollment | Enrollment / accrual |
| NCT00849524 | Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects… | Phase 2 | terminated | Feb 24, 2009 | Januario Castro, M.D. | drug supply became unavailable | Drug supply |
| NCT00942409 | Study of Repeat Intranodal Injections of Ad-ISF35 | Phase 2 | terminated | Jul 20, 2009 | Januario Castro, M.D. | drug supply was no longer available | Drug supply |
| NCT00866281 | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed… | Phase 1 / Phase 2 | terminated | Mar 20, 2009 | Novartis Pharmaceuticals | Despite considerable efforts to boost recruitment during the final year of the study, no new… | Enrollment / accrual |
| NCT01010568 | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | Nov 10, 2009 | Georgetown University | Unable to accrue patients due to change in standard CLL therapy | Enrollment / accrual |
| NCT01049113 | Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia | Phase 1 | terminated | Jan 14, 2010 | Traws Pharma, Inc. | Lack of available clinical drug supply | Drug supply |
| NCT01739491 | A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino… | — | withdrawn | Dec 3, 2012 | Janssen Pharmaceutica | The study is cancelled. FDA Circular 2013-004 mandates that PMSs like this are not required | Other (stated, no rule matched) |
| NCT02034227 | Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic… | Phase 1 / Phase 2 | terminated | Jan 13, 2014 | Spirogen | not stated | Not stated |
| NCT01076556 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell… | Phase 1 | terminated | Feb 26, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01126502 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic… | Phase 1 | terminated | May 19, 2010 | National Cancer Institute (NCI) | Administratively Complete. | Other (stated, no rule matched) |
| NCT01670084 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed… | Phase 2 | withdrawn | Aug 21, 2012 | Mayo Clinic | No Accrual | Enrollment / accrual |
| NCT00924040 | Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | The supply of BL22 has expired and MedImmune the sponsor is not interested in producing any new… | Drug supply |
| NCT02258555 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With… | Phase 1 | terminated | Oct 7, 2014 | Gilead Sciences | not stated | Not stated |
| NCT00587847 | Campath Maintenance in Chronic Lymphocytic Leukemia | N/A | terminated | Jan 8, 2008 | Northwell Health | Insufficient recruitment. | Enrollment / accrual |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in…(LUCID) | Phase 2 | terminated | Oct 23, 2006 | Biogen | not stated | Not stated |
| NCT00801060 | Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR)… | Phase 2 | terminated | Dec 3, 2008 | Biogen | not stated | Not stated |
| NCT00860535 | Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED) | Phase 1 | terminated | Mar 12, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01625741 | Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients…(HYDRIC) | Phase 2 | terminated | Jun 21, 2012 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Stopped by Principal Investigator decision | Investigator |
| NCT02338050 | Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic… | Phase 2 | terminated | Jan 14, 2015 | Center for International Blood and Marrow Transplant Research | not stated | Not stated |
| NCT00569179 | A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype… | Phase 1 | terminated | Dec 7, 2007 | Indiana University | Slow accrual | Enrollment / accrual |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT00363779 | Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular… | Phase 2 | terminated | Aug 15, 2006 | National Cancer Institute (NCI) | Study terminated due to low accrual and the investigator left the NIH. | Investigator |
| NCT00905398 | Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute…(ALLPhi) | Phase 1 / Phase 2 | terminated | May 20, 2009 | Rony Schaffel | The study was terminated due to excessive toxicity and low compliance to the protocol scheme. | Safety / toxicity |
| NCT00413478 | 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia | Phase 2 | terminated | Dec 19, 2006 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT00771602 | Alemtuzumab + Rituximab Consolidation in CLL | Phase 2 | terminated | Oct 13, 2008 | M.D. Anderson Cancer Center | Lack of accrual. | Enrollment / accrual |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients… | Phase 1 | terminated | Aug 21, 2009 | University Health Network, Toronto | not stated | Not stated |
| NCT01271283 | Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia | Phase 2 | withdrawn | Jan 6, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01397149 | Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study… | Phase 1 / Phase 2 | terminated | Jul 19, 2011 | University of Ulm | Insufficient recruitment | Enrollment / accrual |
| NCT00100152 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic… | Phase 1 | terminated | Dec 24, 2004 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01463852 | A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation… | Early Phase 1 | terminated | Nov 2, 2011 | Dartmouth-Hitchcock Medical Center | Enrollment underperformance. | Enrollment / accrual |
| NCT00944008 | PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of…(2009-009422-92) | Phase 3 | terminated | Jul 22, 2009 | PETHEMA Foundation | not stated | Not stated |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With… | N/A | withdrawn | Jan 17, 2013 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00262925 | Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory… | Phase 2 | terminated | Dec 7, 2005 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT00093314 | HuMax-CD20 in Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | withdrawn | Oct 8, 2004 | GlaxoSmithKline | Acquired asset | Other (stated, no rule matched) |
| NCT01100658 | Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors | N/A | terminated | Apr 9, 2010 | University of Minnesota | Due to slow accrual | Enrollment / accrual |
| NCT00845104 | Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell… | Phase 2 | withdrawn | Feb 18, 2009 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | No patients enrolled. | Enrollment / accrual |
| NCT00916045 | Pilot Study of Unrelated Cord Blood Transplantation | Phase 2 | terminated | Jun 8, 2009 | King's College Hospital NHS Trust | Recruitment issues | Enrollment / accrual |
| NCT00798213 | SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia… | Phase 2 | terminated | Nov 26, 2008 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01486043 | Metformin and Transient Hyperglycemia | N/A | terminated | Dec 6, 2011 | Children's Hospital Los Angeles | The research project was terminated due to lower than projected patient recruitment within the… | Enrollment / accrual |
| NCT01230788 | Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia(Rituximab) | N/A | terminated | Oct 29, 2010 | Emory University | Lack of enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Jun 21, 2016source: clinicaltrials